Inherited metabolic disorders and cerebral infarction

References

• Meschia JF, Case LD, Worrall BB et al. Family history of stroke and severity of neurologic deficit after stroke. Neurology67, 1396–1402 (2006).
   PubMed Web of Science ®Google Scholar
• Varret M, Abifadel M, Rabès JP, Boileau C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin. Genet.73, 1–13 (2008).
   PubMed Web of Science ®Google Scholar
• Norman D, Sun XM, Bourbon M, Knight BL, Naoumova RP, Soutar AK. Characterization of a novel cellular defect in patients with phenotypic homozygous familial hypercholesterolemia. J. Clin. Invest.104, 619–628 (1999).
   PubMedGoogle Scholar
• Yuan G, Wang J, Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ174, 1124–1129 (2006).
   PubMed Web of Science ®Google Scholar
• Hobbs HH, Brown MS, Russell DW et al. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N. Engl. J. Med.317, 734–737 (1987).
   PubMed Web of Science ®Google Scholar
• Mishra SK, Bose TK, Das BS. Homozygous familial hypercholesterolaemia. Report of three cases. J. Assoc. Physicians India39, 344–345 (1991).
   Google Scholar
• Gagné C, Moorjani S, Brun D et al. Heterozygous familial hypercholesterolemia: relationship between plasma lipids, lipoproteins, clinical manifestations and ischaemic heart disease in men and women. Atherosclerosis34, 13–24 (1979).
   PubMed Web of Science ®Google Scholar
• Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis168, 1–14 (2003).
   PubMed Web of Science ®Google Scholar
• Sibley C, Stone NJ. Familial hypercholesterolemia: a challenge of diagnosis and therapy. Cleve. Clin. J. Med.73, 57–64 (2006).
   PubMed Web of Science ®Google Scholar
• Marais AD, Firth JC, Blom DJ. Homozygous familial hypercholesterolemia and its management. Semin. Vasc. Med.4, 43–50 (2004).
   PubMedGoogle Scholar
• Rubba P, Mercuri M, Faccenda F et al. Premature carotid atherosclerosis: does it occur in both familial hypercholesterolemia and homocystinuria? Ultrasound assessment of arterial intima-media thickness and blood flow velocity. Stroke25, 943–950 (1994).
   Google Scholar
• Soljanlahti S, Autti T, Lauerma K et al. Familial hypercholesterolemia patients treated with statins at no increased risk for intracranial vascular lesions despite increased cholesterol burden and extracranial atherosclerosis. Stroke36, 1572–1574 (2005).
   PubMedGoogle Scholar
• Rodriguez G, Bertolini S, Nobili F et al. Regional cerebral blood flow in familial hypercholesterolemia. Stroke25, 831–836 (1994).
   PubMed Web of Science ®Google Scholar
• Williams RR, Hunt SC, Schumacher MC et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol.72, 171–176 (1993).
   PubMed Web of Science ®Google Scholar
• Huijgen R, Vissers MN, Defesche JC, Lansberg PJ, Kastelein JJ, Hutten BA. Familial hypercholesterolemia: current treatment and advances in management. Expert Rev. Cardiovasc. Ther.6, 567–581 (2008).
   PubMedGoogle Scholar
• Avis HJ, Vissers MN, Stein EA et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol.27, 1803–1810 (2007).
   PubMed Web of Science ®Google Scholar
• Marais AD, Raal FJ, Stein EA et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis197, 400–406 (2008).
   PubMed Web of Science ®Google Scholar
• Marais AD, Blom DJ, Firth JC. Statins in homozygous familial hypercholesterolemia. Curr. Atheroscler. Rep.4, 19–25 (2002).
   PubMedGoogle Scholar
• Alonso R, Mata N, Mata P. Benefits and risks assessment of simvastatin in familial hypercholesterolaemia. Expert Opin. Drug Saf.4, 171–181 (2005).
   PubMedGoogle Scholar
• Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med.358, 1431–1443 (2008).
   PubMed Web of Science ®Google Scholar
• Makino H, Harada-Shiba M. Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Ther. Apher. Dial.7, 397–401 (2003).
   Google Scholar
• Banyai S, Banyai M, Falger J et al. Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment. Atherosclerosis159, 513–519 (2001).
   PubMed Web of Science ®Google Scholar
• Møller AT, Jensen TS. Neurological manifestations in Fabry’s disease. Nat. Clin. Pract. Neurol.3, 95–106 (2007).
   Google Scholar
• Giacomini PS, Shannon PT, Clarke JT, Jaigobin C. Fabry’s disease presenting as stroke in a young female. Can. J. Neurol. Sci.31, 112–114 (2004).
   Google Scholar
• Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann. Neurol.40, 8–17 (1996).
   PubMed Web of Science ®Google Scholar
• Crutchfield KE, Patronas NJ, Dambrosia JM et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology50, 1746–1749 (1998).
   PubMed Web of Science ®Google Scholar
• Grewal RP. Stroke in Fabry’s disease. J. Neurol.241, 153–156 (1994).
   Google Scholar
• Rolfs A, Böttcher T, Zschiesche M et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet366, 1794–1796 (2005).
   PubMed Web of Science ®Google Scholar
• Burlina AP, Manara R, Caillaud C et al. The pulvinar sign: frequency and clinical correlations in Fabry disease. J. Neurol.255, 738–744 (2008).
   Google Scholar
• Grewal RP, McLatchey SK. Cerebrovascular manifestations in a female carrier of Fabry’s disease. Acta Neurol. Belg.92, 36–40 (1992).
   Google Scholar
• Ritter M, Dittrich R, Droste DW. Microembolus detection in four patients with Fabry’s disease: further support for a primarily microangiopathic origin of early cerebrovascular symptoms. Eur. Neurol.50, 141–145 (2003).
   PubMed Web of Science ®Google Scholar
• Mehta A, Ricci R, Widmer U et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur. J. Clin. Invest.34, 236–242 (2004).
   PubMed Web of Science ®Google Scholar
• Desnick RJ, Brady R, Barranger J et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann. Intern. Med.138, 338–346 (2003).
   PubMed Web of Science ®Google Scholar
• Wilcox WR, Banikazemi M, Guffon N et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet.75, 65–74 (2004).
   PubMed Web of Science ®Google Scholar
• Moore DF, Altarescu G, Ling GS et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke33, 525–531 (2002).
   PubMed Web of Science ®Google Scholar
• Moore DF, Scott LT, Gladwin MT et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation104, 1506–1512 (2001).
   PubMed Web of Science ®Google Scholar
• Moghadasian MH, Salen G, Frohlich JJ, Scudamore CH. Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch. Neurol.59, 527–529 (2002).
   PubMedGoogle Scholar
• Valdivielso P, Calandra S, Durán JC, Garuti R, Herrera E, González P. Coronary heart disease in a patient with cerebrotendinous xanthomatosis. J. Intern. Med.255, 680–683 (2004).
   Google Scholar
• Joo IS, Cho PZ, Kim DI. A case of cerebrotendinous xanthomatosis associated with cerebral infarction. J. Korean Neurol. Assoc.6, 91–96 (1988).
   Google Scholar
• Potkin BN, Hoeg JM, Connor WE et al. Aneurysmal coronary artery disease in cerebrotendinous xanthomatosis. Am. J. Cardiol.61, 1150–1152 (1988).
   Google Scholar
• Shore V, Salen G, Cheng FW et al. Abnormal high density lipoproteins in cerebrotendinous xanthomatosis. J. Clin. Invest.68, 1295–1304 (1981).
   Google Scholar
• Panzenboeck U, Andersson U, Hansson M, Sattler W, Meaney S, Björkhem I. On the mechanism of cerebral accumulation of cholestanol in patients with cerebrotendinous xanthomatosis. J. Lipid Res.48, 1167–1174 (2007).
   Google Scholar
• Lorincz MT, Rainier S, Thomas D, Fink JK. Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. Arch. Neurol.62, 1459–1463 (2005).
   PubMed Web of Science ®Google Scholar
• Smithard A, Lamyman MJ, McCarthy CL, Gibbons CL, Cooke PJ, Athanasou N. Cerebrotendinous xanthomatosis presenting with bilateral Achilles tendon xanthomata. Skeletal Radiol.36, 171–175 (2007).
   Google Scholar
• Muhammed K, Nandakumar G, Saritha S. Cerebrotendinous xanthomatosis: need for early diagnosis. Indian J. Dermatol. Venereol. Leprol.72, 364–366 (2006).
   Google Scholar
• De Stefano N, Dotti MT, Mortilla M, Federico A. Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain124, 121–131 (2001).
   PubMed Web of Science ®Google Scholar
• Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N. Engl. J. Med.311, 1649–1652 (1984).
   PubMed Web of Science ®Google Scholar
• Verrips A, Wevers RA, Van Engelen BG et al. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism48, 233–238 (1999).
   Google Scholar
• Bojanovski D, Gregg RE, Brewer HB Jr. Tangier disease. In vitro conversion of proapo-A-ITangier to mature APO-A-ITangier. J. Biol. Chem.259, 6049–6051 (1984)
   Google Scholar
• Tall AR, Wang N. Tangier disease as a test of the reverse cholesterol transport hypothesis. J. Clin. Invest.106, 1205–1207 (2000).
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Mikhailidis DP, Anagnostopoulou KK, Daskalopoulou SS, Cokkinos DV. Tangier disease four decades of research: a reflection of the importance of HDL. Curr. Med. Chem.13, 771–782 (2006).
   PubMedGoogle Scholar
• Oram JF. Tangier disease and ABCA1. Biochim. Biophys. Acta.1529, 321–330 (2000).
   PubMed Web of Science ®Google Scholar
• Serfaty-Lacrosniere C, Civeira F, Lanzberg A et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis107, 85–98 (1994).
   PubMed Web of Science ®Google Scholar
• Brooks-Wilson A, Marcil M, Clee SM et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet.22, 336–345 (1999).
   PubMed Web of Science ®Google Scholar
• Asztalos BF, Brousseau ME, McNamara JR, Horvath KV, Roheim PS, Schaefer EJ. Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease. Atherosclerosis156, 217–225 (2001).
   PubMed Web of Science ®Google Scholar
• Sinha S, Mahadevan A, Lokesh L et al. Tangier disease: a diagnostic challenge in countries endemic for leprosy. J. Neurol. Neurosurg. Psychiatry75, 301–304 (2004).
   Google Scholar
• Natowicz M, Kelley RI. Mendelian etiologies of stroke. Ann. Neurol.22, 175–192 (1987).
   PubMedGoogle Scholar
• Kraus JP, Janosík M, Kozich V et al. Cystathionine β-synthase mutations in homocystinuria. Hum. Mutat.13, 362–375 (1999).
   PubMed Web of Science ®Google Scholar
• Varga EA, Sturm AC, Misita CP, Moll S. Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease. Circulation111, e289–e293 (2005).
   Web of Science ®Google Scholar
• Meschia JF, Brott TG, Brown RD Jr. Genetics of cerebrovascular disorders. Mayo Clin. Proc.80, 122–132 (2005).
   PubMed Web of Science ®Google Scholar
• Cruysberg JR, Boers GH, Trijbels JM, Deutman AF. Delay in diagnosis of homocystinuria: retrospective study of consecutive patients. BMJ313, 1037–1040 (1996)
   Google Scholar
• Buoni S, Di Bartolo RM, Molinelli M, Palmeri S, Zannolli R. Atypical BECTS and homocystinuria. Neurology61, 1129–1131 (2003).
   Google Scholar
• Clarke R, Lewington S. Homocysteine and coronary heart disease. Semin. Vasc. Med.2, 391–399 (2002).
   Google Scholar
• Casas JP, Bautista LE, Smeeth L et al. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet365, 224–232 (2005).
   PubMed Web of Science ®Google Scholar
• Carson NAJ. Homocystinuria: clinical and biochemical heterogeneity. In: Inborn Errors of Metabolism in Humans. Cockburn F, Gitzelmann R (Eds). MTP Press Ltd, Lancaster, UK 53–67 (1982).
   Google Scholar
• van Guldener C, Stehouwer CD. Homocysteine and large arteries. Adv. Cardiol.44, 278–301 (2007).
   Google Scholar
• Cardo E, Campistol J, Caritg J et al. Fatal haemorrhagic infarct in an infant with homocystinuria. Dev. Med. Child. Neurol.41, 132–135 (1999).
   Google Scholar
• Kelly PJ, Furie KL, Kistler JP et al. Stroke in young patients with hyperhomocysteinemia due to cystathionine β-synthase deficiency. Neurology60, 275–279 (2003).
   PubMed Web of Science ®Google Scholar
• Weiss N, Demeret S, Sonneville R, Guillevin R, Bolgert F, Pierrot-Deseilligny C. Bilateral internal carotid artery dissection in cystathionine β-synthase deficiency. Eur. Neurol.55, 177–178 (2006).
   PubMed Web of Science ®Google Scholar
• Bittles AH, Carson NA. Homocystinuria: studies on cystathionine beta-synthase, S-adenosylmethionine synthetase and cystathionase activities in skin fibroblasts. J. Inherit. Metab. Dis.4, 3–6 (1981).
   Google Scholar
• Chace DH, Hillman SL, Millington DS, Kahler SG, Adam BW, Levy HL. Rapid diagnosis of homocystinuria and other hypermethioninemias from newborns’ blood spots by tandem mass spectrometry. Clin. Chem.42, 349–355 (1996).
   Google Scholar
• Mahfoud A, Domínguez CL, Pérez A, Rizzo C, Merinero B, Pérez B. Diagnosis and treatment of methylmalonic aciduria: a case report. Invest. Clin.48, 99–105 (2007).
   Google Scholar
• Chandler RJ, Venditti CP. Genetic and genomic systems to study methylmalonic acidemia. Mol. Genet. Metab.86, 34–43 (2005).
   Google Scholar
• Shigematsu Y, Hirano S, Hata I et al. Newborn mass screening and selective screening using electrospray tandem mass spectrometry in Japan. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.776, 39–48 (2002).
   PubMed Web of Science ®Google Scholar
• Coulombe JT, Shih VE, Levy HL. Massachusetts Metabolic Disorders Screening Program. II. Methylmalonic aciduria. Pediatrics67, 26–31 (1981).
   PubMedGoogle Scholar
• Nicolaides P, Leonard J, Surtees R. Neurological outcome of methylmalonic acidaemia. Arch. Dis. Child.78, 508–512 (1998).
   PubMedGoogle Scholar
• Matsui SM, Mahoney MJ, Rosenberg LE. The natural history of the inherited methylmalonic acidemias. N. Engl. J. Med.308, 857–861 (1983).
   Google Scholar
• Heidenreich R, Natowicz M, Hainline BE et al. Acute extrapyramidal syndrome in methylmalonic acidemia: “metabolic stroke” involving the globus pallidus. J. Pediatr.113, 1022–1027 (1988).
   Google Scholar
• Chakrapani A, Sivakumar P, McKiernan PJ, Leonard JV. Metabolic stroke in methylmalonic acidemia five years after liver transplantation. J. Pediatr.140, 261–263 (2002).
   PubMed Web of Science ®Google Scholar
• Wajner M, Coelho JC. Neurological dysfunction in methylmalonic acidaemia is probably related to the inhibitory effect of methylmalonate on brain energy production. J. Inherit. Metab. Dis.20, 761–768 (1997).
   PubMedGoogle Scholar
• Roze E, Gervais D, Demeret S et al. Neuropsychiatric disturbances in presumed late-onset cobalamin C disease. Arch. Neurol.60, 1457–1462 (2003).
   Google Scholar
• Rashed MS, Ozand PT, Bucknall MP, Little D. Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry. Pediatr. Res.38, 324–331 (1995).
   PubMed Web of Science ®Google Scholar
• Tanpaiboon P. Methylmalonic acidemia (MMA). Mol. Genet. Metab.85, 2–6 (2005).
   PubMedGoogle Scholar
• Trinh BC, Melhem ER, Barker PB. Multi-slice proton MR spectroscopy and diffusion-weighted imaging in methylmalonic acidemia: report of two cases and review of the literature. AJNR Am. J. Neuroradiol.22, 831–833 (2001).
   Google Scholar
• McGuire PJ, Lim-Melia E, Diaz GA et al. Combined liver-kidney transplant for the management of methylmalonic aciduria: a case report and review of the literature. Mol. Genet. Metab.93, 22–29 (2008).
   Google Scholar
• Smith WE, Millington DS, Koeberl DD. Glutaric acidemia, type I , missed by newborn screening in and Infant with dystonia following promethazine administration. Pediatrics107, 1184–1187 (2001).
   Google Scholar
• Kolker S, Christensen E, Leonard JV et al. Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). J. Inherit. Metab. Dis.30, 5–22 (2007).
   Google Scholar
• Gordon N. Glutaric aciduria types I and II. Brain Dev.28, 136–140 (2006).
   Google Scholar
• Strauss KA, Morton DH. Type I glutaric aciduria, part 2, a modal of acute striatal necrosis. Am. J. Med. Genet.121, 53–70 (2003).
   Google Scholar
• Twomey EL, Naughten ER, Donoghue VB, Ryan S. Neuroimaging findings in glutaric aciduria type I. Pedriatr. Radiol.33, 823–830 (2003).
   PubMed Web of Science ®Google Scholar
• Lamhonwah AM, Barankiewicz TJ, Willard HF, Mahuran DJ, Quan F, Gravel RA. Isolation of cDNA clones coding for the α and β chains of human propionyl-CoA carboxylase: chromosomal assignments and DNA polymorphisms associated with PCCA and PCCB genes. Proc. Natl Acad. Sci. USA83, 4864–4868 (1986).
   PubMed Web of Science ®Google Scholar
• Delgado C, Macías C, de la Sierra García-Valdecasas M, Pérez M, del Portal LR, Jiménez LM. Subacute presentation of propionic acidemia. J. Child. Neurol.22, 1405–1407 (2007).
   Google Scholar
• Nyhan WL, Bay C, Beyer EW, Mazi M. Neurologic nonmetabolic presentation of propionic academia. Arch. Neurol.56, 1143–1147 (1999).
   Google Scholar
• Harker HE, Emhardt JD, Hainline BE. Propionic acidemia in a four-month-old male: a case study and anesthetic implications. Anesth. Analg.91, 309–311 (2000).
   Google Scholar
• Wolf B, Hsia YE, Sweetman L, Gravel R, Harris DJ, Nyhan WL. Propionic acidemia: a clinical update. J. Pediatr.99, 835–846 (1981).
   PubMed Web of Science ®Google Scholar
• Rela M, Battula N, Madanur M et al. Auxiliary liver transplantation for propionic acidemia: a 10-year follow-up. Am. J. Transplant.7, 2200–2203 (2007).
   PubMed Web of Science ®Google Scholar
• Haas RH, Marsden DL, Capistrano-Estrada S et al. Acute basal ganglia infarction in propionic acidemia. J. Child. Neurol.10, 18–22 (1995).
   PubMed Web of Science ®Google Scholar
• Hamilton RL, Haas RH, Nyhan WL, Powell HC, Grafe MR. Neuropathology of propionic acidemia: a report of two patients with basal ganglia lesions. J. Child. Neurol.10, 25–30 (1995).
   Google Scholar
• Burlina AP, Baracchini C, Carollo C, Burlina AB. Propionic acidaemia with basal ganglia stroke: treatment of acute extrapyramidal symptoms with l-DOPA. J. Inherit. Metab. Dis.24, 596–598 (2001).
   Google Scholar
• Al-Essa M, Bakheet S, Patay Z et al. 18Fluoro-2-deoxyglucose (18FDG) PET scan of the brain in propionic acidemia: clinical and MRI correlations. Brain Dev.21, 312–317 (1999).
   Google Scholar
• Brismar J, Ozand PT. CT and MR of the brain in disorders of the propionate and methylmalonate metabolism. AJNR Am. J. Neuroradiol.15, 1459–1473 (1994).
   PubMed Web of Science ®Google Scholar
• Sweetman L, Weyler W, Shafai T, Young PE, Nyhan WL. Prenatal diagnosis of propionic acidemia. JAMA242, 1048–1052 (1979).
   Google Scholar
• Pérez-Cerdá C, Merinero B, Martí M et al. An unusual late-onset case of propionic acidaemia: biochemical investigations, neuroradiological findings and mutation analysis. Eur. J. Pediatr.157, 50–52 (1998).
   Google Scholar
• Hirano M, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): current concepts. J. Child. Neurology9, 4–13 (1994).
   PubMed Web of Science ®Google Scholar
• Kaufmann P. Cerebral lactic acidodis correlates with neurological impairment in MELAS Neurol.62, 1297–1302 (2004).
   PubMed Web of Science ®Google Scholar
• Silliman S. Mendelian and mitochondrial disorders associated with stroke. J. Stroke Cerebrovasc. Dis.11, 252–264 (2002).
   Google Scholar
• Manwaring N, Jones MM, Wang JJ et al. Population prevalence of the MELAS A3243G mutation. Mitochondrion7, 230–233 (2007).
   PubMed Web of Science ®Google Scholar
• Silbert L, Durocher, A, Biller, J. The “S” in MELAS. J. Stroke Cerebrovasc. Dis.6, 67–71 (1996).
   Google Scholar
• Shoffner JM, Wallace DC. Oxidative phosphorylation disease and stroke. Heart Dis. Stroke2, 439–445 (1993).
   Google Scholar
• Thambisetty M, Newman NJ, Glass JD, Frankel MR. A practical approach to the diagnosis and management of MELAS: case report and review. Neurologist8302–8312 (2002).
   Google Scholar
• Yamamoto T, Beppu H, Tsubaki T. Mitochondrial encephalomyopathy: fluctuating symptoms and CT. Neurology34, 1456–1460 (1984).
   PubMedGoogle Scholar
• Yoneda M, Maeda M, Kimura H, Fujii A, Katayama K, Kuriyama M. Vasogenic edema on MELAS: a serial study with diffusion-weighted MR imaging. Neurology53, 2182–2184 (1999).
   PubMedGoogle Scholar
• Ohama E, Ohara S, Ikuta R, Tanaka K Nishizawa M, Miyatake T. Mitochondrial angiopathy in cerebral vessels of mitochondrial encephalomyopahty. Acta Neuropath. (Berl.)74, 226–233 (1987).
   PubMed Web of Science ®Google Scholar
• Scaglia F, Northrop JL. The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options. CNS Drugs20, 443–464 (2006).
   PubMed Web of Science ®Google Scholar
• Lindgren V, de Martinville B, Horwich AL, Rosenberg LE, Francke U. Human ornithine transcarbamylase locus mapped to band Xp21.1 near the Duchenne muscular dystrophy locus. Science226, 698–700 (1984).
   PubMedGoogle Scholar
• Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology and therapy. Adv. Pediatr.43, 127–170 (1996).
   PubMedGoogle Scholar
• Hu WT, Kantarci HO, Merritt II JL et al. Ornithine transcarbamylase deficiency presenting as encephalopathy during adulthood following bariatric surgery. Arch. Neurol.64, 126–128 (2007).
   Google Scholar
• Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of girls with ornithine transcarbamylase deficiency. N. Engl. J. Med.335, 855–859 (1996).
   PubMed Web of Science ®Google Scholar
• Gordon N. Ornithine transcarbamylase deficiency: a urea cycle defect. Eur. J. Paediatr. Neurol.7, 115–121 (2003).
   PubMed Web of Science ®Google Scholar
• Yoshino M, Nishiyori J, Yamashita F et al. Ornithine transcarbamylase deficiency in male adolescence and adulthood. Enzyme43, 160–168 (1990).
   Google Scholar
• Legras A, Labarthe F, Maillot F, Garrigue MA, Kouatchet A, Ogier de Baulny H. Late diagnosis of ornithine transcarbamylase defect in three related female patients: polymorphic presentations. Crit. Care Med.30, 241–244 (2002).
   PubMed Web of Science ®Google Scholar
• de Grauw TJ, Smit LM, Brockstedt M, Meijer Y, vd Klei-von Moorsel J, Jakobs C. Acute hemiparesis as the presenting sign in a heterozygote for ornithine transcarbamylase deficiency. Neuropediatrics21, 133–135 (1990).
   Google Scholar
• Christodoulou J, Qureshi IA, McInnes RR, Clarke JT. Ornithine transcarbamylase deficiency presenting with strokelike episodes. J. Pediatr.122, 423–425 (1993).
   Google Scholar
• Keegan CE, Martin DM, Quint DJ, Gorski JL. Acute extrapyramidal syndrome in mild ornithine transcarbamylase deficiency: metabolic stroke involving the caudate and putamen without metabolic decompensation. Eur. J. Pediatr.162, 259–263 (2003).
   Google Scholar
• Michalak A, Butterworth RF. Ornithine transcarbamylase deficiency: pathogenesis of the cerebral disorder and new prospects for therapy. Metab. Brain Dis.12, 171–182 (1997).
   Google Scholar
• Takanashi J, Barkovich AJ, Cheng SF, Kostiner D, Baker JC, Packman S. Brain MR imaging in acute hyperammonemic encephalopathy arising from late-onset ornithine transcarbamylase deficiency. AJNR Am. J. Neuroradiol.24, 390–393 (2003).
   Google Scholar
• Steiner RD, Cederbaum SD. Laboratory evaluation of urea cycle disorders. J. Pediatr.138, S21–S29 (2001).
   Google Scholar
• Chiong MA, Carpenter K, Christodoulou J. Low citrulline may not be diagnostic of ornithine transcarbamylase deficiency: a case report. J. Inherit. Metab. Dis.30, 405 (2007).
   Google Scholar
• Arranz JA, Riudor E, Rodés M et al. Optimization of allopurinol challenge: sample purification, protein intake control, and the use of orotidine response as a discriminative variable improve performance of the test for diagnosing ornithine carbamoyltransferase deficiency. Clin. Chem.45, 995–1001 (1999).
   Google Scholar
• Grünewald S, Fairbanks L, Genet S et al. How reliable is the allopurinol load in detecting carriers for ornithine transcarbamylase deficiency? J. Inherit. Metab. Dis.27, 179–186 (2004).
   Google Scholar
• Nagasaka H, Yorifuji T, Murayama K et al. Effects of arginine treatment on nutrition, growth and urea cycle function in seven Japanese boys with late-onset ornithine transcarbamylase deficiency. Eur. J. Pediatr.165, 618–624 (2006).
   Google Scholar